NCT02215980已完成3 期
A PHASE III, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS
Fondazione EMN Italy Onlus1 个研究点 分布在 1 个国家目标入组 210 人开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 210
- 试验地点
- 1
- 主要终点
- Event-free survival
研究概览
简要总结
This protocol is a phase III multicenter, randomized, controlled study designed to assess the safety and the efficacy of standard schedule versus a new algoritm of dose reductions in elderly and unfit newly diagnosed Multiple Myeloma (MM) patients receiving lenalidomide plus steroids.
详细描述
TREATMENT PERIOD:
Arm A: Rd
- Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21.
- Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days until progression or intolerance.
Arm B: Rd-R (reduced)
- Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21
- Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days, for a total of 9 cycles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients >65 years unfit and unsuitable, according to the investigator's opinion, to receive approved first line treatments for newly diagnosed MM.
- •Patient is, in the investigator(s) opinion, willing and able to comply with the protocol requirements.
- •Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- •Symptomatic MM based on standard CRAB criteria (5).
- •Patient has measurable disease, defined as follows: any quantifiable serum monoclonal protein value (generally, but not necessarily, ≥ 0.5 g/dL of M-protein) and, where applicable, urine light-chain excretion of >200 mg/24 hours. For patients with oligo or non-secretory MM, it is required that they have measurable plasmacytoma > 2 cm as determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan) or an abnormal free light chain ratio (n.v.: 0.26-1.65). We anticipate that less than 10% of patients admitted to this study will be oligo- or non-secretory MM with free light chains only in order to maximize interpretation of benefit results.
- •All randomized patients will be selected based on the use of 3 geriatric scales: IADL, ADL, Charlson. Unfit patients with clinical sign of frailty (mild, moderate or severe frailty), including need help for household tasks and personal care can be enrolled in this trial (2,4).
- •In order to include patients who normally are not select for clinical trials, also patients with the following abnormal laboratory values can be considered:
- •absolute neutrophil count (ANC) < 1 x 10^9/L
- •platelet count < 80 x 10^9/L
- •haemoglobin < 8 g/dl.
- •aspartate transaminase (AST): < 5 x the upper limit of normal (ULN).
- •alanine transaminase (ALT): < 5 x the ULN.
- •total bilirubin: > 1.5 x the ULN
- •calculated or measured creatinine clearance: <30 mL/minute
- •The geriatric assessment evaluations will select unfit patients to be randomized regardless of possible abnormal laboratory values at the study entry.
排除标准
- •Pregnant or lactating females.
- •Male patients not agreeing to use an acceptable method for contraception (i.e., condom or abstinence) for the duration of the study.
- •Females of childbearing potential not agreeing to use two acceptable methods for contraception (e.g. a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
- •Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid < to the equivalent of dexamethasone 40 mg/day for 4 days).
- •Any significant medical disease or conditions that, in the investigator's opinion, may interfere with protocol adherence or subject's ability to give informed consent or could place the subject at unacceptable risk.
- •Presence of clinical active infectious hepatitis type B or C, classified into Child-Pugh class C (see Appendix V) and HIV.
- •Presence of acute active infection requiring antibiotics or infiltrative pulmonary disease.
- •Contraindication to any of the required drugs or supportive treatments.
- •Presence of prior history of malignancies, other than multiple myeloma, with a life expectancy < 2 years.
- •Known allergy to any of the study medications, their analogues, or excipients in the various formulations.
研究组 & 干预措施
A
Experimental
- Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21.
- Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days until progression or intolerance.
干预措施: Lenalidomide (Drug)
A
Experimental
- Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21.
- Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days until progression or intolerance.
干预措施: Dexamethasone (Drug)
B
Experimental
- Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21
- Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days, for a total of 9 cycles.
Maintenance until progression or intolerance:
- Lenalidomide: 10 mg/daily on days 1-21 of each 28-day cycle
干预措施: Lenalidomide (Drug)
B
Experimental
- Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21
- Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days, for a total of 9 cycles.
Maintenance until progression or intolerance:
- Lenalidomide: 10 mg/daily on days 1-21 of each 28-day cycle
干预措施: Dexamethasone (Drug)
结局指标
主要结局
Event-free survival
时间窗: 3 years
Determine the Event-free survival defined as: * Progression * Death for any cause * Discontinuation of lenalidomide therapy * Occurrence of any haematological grade 4 or non-haematological grade 3-4 adverse events (AES), including Secondary Primary Malignancies (SPMs)
次要结局
- Incidence of dose reduction and drug discontinuation(5 years)
- Progression-free survival (PFS)(5 years)
- Overall survival (OS)(5 years)
- Duration of response (DOR)(5 years)
- Time to response (TTR)(5 years)
- Time to the next therapy (TNT)(5 years)
- Time to progression (TTP)(5 years)
- Overall response rate (ORR)(5 years)
- Health care cost(5 years)
- Correlation between tumor response and outcome with baseline prognostic factors(5 years)
- Quality of life assessment (HRQOL)(5 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart FailureHeart Failure With Reduced Ejection FractionVascular DiseasesCardiovascular DiseasesHeart Failure With Preserved Ejection FractionHeart Failure With Mid Range Ejection FractionHypertensionHeart FailurePulmonary HypertensionNCT05824923Pulnovo Medical (Wuxi) Co., Ltd.264
已完成
3 期
Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent PatientsGastroesophageal Reflux Disease (GERD)NCT00241501AstraZeneca140
招募中
不适用
A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric CancerGastric CancerNCT04843215Tianjin Medical University Cancer Institute and Hospital950
已完成
3 期
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's DiseaseCushing's DiseaseNCT01374906Novartis Pharmaceuticals150
终止
3 期
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to InfluenzaCoughSore ThroatNasal CongestionHeadacheFeverSeasonal InfluenzaNCT00958776BioCryst Pharmaceuticals405